Does AmeriHealth Cover GLP-1? Commercial, Medicaid, and Denials

AmeriHealth does cover GLP-1 medications, but only when they are prescribed for an FDA-approved medical condition such as type 2 diabetes or cardiovascular risk reduction, and prior authorization is required. As of January 1, 2025, AmeriHealth commercial plans stopped paying for GLP-1 drugs prescribed solely for weight loss, and AmeriHealth Caritas Medicaid plans in several states have followed with similar restrictions. Whether your specific prescription is covered comes down to three things: your diagnosis, the type of plan you have, and in some cases whether your employer bought an optional weight-loss benefit.

Commercial Plans and the 2025 Weight-Loss Exclusion

AmeriHealth HMO, Inc. and AmeriHealth Insurance Company of New Jersey stopped covering GLP-1 and non-GLP-1 receptor agonist drugs prescribed solely for weight loss effective January 1, 2025. The exclusion applies to fully insured group and individual commercial members. Anyone who had been taking one of these drugs for weight loss became responsible for the full cost on that date or at plan renewal. AmeriHealth pointed to the price of these medications in the United States, which it said runs nearly ten times higher than in other countries.1AmeriHealth Provider Communications. Changes Coming to Weight Loss Drug Coverage Benefits

If your doctor prescribes a GLP-1 for type 2 diabetes, cardiovascular disease, or another FDA-approved indication, coverage continues under the standard pharmacy benefit, subject to prior authorization.1AmeriHealth Provider Communications. Changes Coming to Weight Loss Drug Coverage Benefits Medicare plans do not cover GLP-1s for weight loss at all, though Medicare permits coverage of Wegovy for its cardiovascular indication.

There is one way to keep weight-loss coverage on a commercial AmeriHealth plan: an employer-added weight-loss benefit rider. Employers choose whether to include it, and most do not. Providers can check whether a specific member has this benefit using the Eligibility and Benefits transaction in the PEAR portal.2AmeriHealth Provider Communications. AmeriHealth to End Commercial Coverage of Zepbound for OSA If you are not sure whether your plan has the rider, ask your HR department or call the member services number on your card before filling a prescription.

Zepbound for Sleep Apnea Is No Longer Covered

If you were counting on Zepbound (tirzepatide) to treat obstructive sleep apnea, that door has closed on commercial AmeriHealth plans. New prescriptions for OSA stopped being covered on May 1, 2025. Existing prescriptions ended on August 1, 2025, or at plan renewal, whichever came first. AmeriHealth said the clinical evidence for using Zepbound in OSA beyond its weight-loss effect was limited, and listed CPAP, BiPAP, oral devices, nerve stimulators, and surgery as covered alternatives.2AmeriHealth Provider Communications. AmeriHealth to End Commercial Coverage of Zepbound for OSA

Prior Authorization for Type 2 Diabetes

GLP-1 receptor agonists prescribed for type 2 diabetes have required prior authorization on both the Select Drug Program Formulary and the Value Formulary since April 1, 2023.3AmeriHealth Provider Communications. Reminder: Glucagon-Like Peptide-1 Receptor Agonists The clinical criteria your prescriber must meet appear in the formulary documents for your specific plan.

The Select Drug Program Formulary includes Adlyxin, Bydureon BCise, Byetta, and exenatide injection among its GLP-1 options.4AmeriHealth. Select Drug Program Formulary Guide A January 2026 formulary update placed exenatide injection (Byetta) in the non-preferred tier with prior authorization and a quantity limit.5AmeriHealth. NJ Formulary Changes January 2026 A drug not listed on the formulary can still be considered through a medical necessity request.

AmeriHealth Caritas Medicaid Coverage by State

AmeriHealth Caritas administers Medicaid managed care in several states, and each state sets its own rules for GLP-1 coverage. Federal law requires state Medicaid programs to cover nearly all FDA-approved drugs, but a long-standing exception lets states decide whether to pay for drugs used for weight loss.6KFF. Medicaid Coverage of and Spending on GLP-1s Here is where things stand in the states AmeriHealth Caritas serves.

Pennsylvania

Pennsylvania Medicaid ended GLP-1 coverage for weight loss in adults 21 and older effective January 1, 2026. Saxenda (liraglutide) lost coverage for all indications.7Pennsylvania Department of Human Services. Medical Assistance Bulletin 2025112403 Adults can still get a GLP-1 covered if it is prescribed for type 2 diabetes, obstructive sleep apnea with obesity, cardiovascular risk reduction, or noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), with prior authorization.8AmeriHealth Caritas PA. GLP-1 Receptor Agonists Prior Authorization Form Beneficiaries under 21 remain eligible for weight-loss GLP-1s under the federal EPSDT mandate.9Pennsylvania Health Law Project. PA Medicaid Ends Adult Coverage of GLP-1s for Weight Loss Patients already on a GLP-1 needed their doctors to submit new prior authorization requests to avoid a coverage gap.

New Hampshire

New Hampshire Medicaid stopped covering GLP-1s prescribed exclusively for weight loss on January 1, 2026. The affected drugs are Saxenda, Wegovy, Zepbound, and generic equivalents.10AmeriHealth Caritas NH. Change for GLP-1 Medications Coverage continues when a GLP-1 is prescribed for type 2 diabetes, major adverse cardiovascular events, severe obstructive sleep apnea, or MASH.11New Hampshire Bulletin. Medicaid to Stop Covering Weight Loss Drugs for Obesity in New Hampshire

North Carolina

AmeriHealth Caritas NC still covers GLP-1 drugs for weight management, with prior authorization. For adults 18 and older, the initial criteria are a BMI of at least 30, or a BMI of at least 27 with a weight-related comorbidity such as hypertension, type 2 diabetes, or cardiovascular disease. Adolescents 12 to 17 must meet age-adjusted BMI thresholds. All patients must be engaged in lifestyle modification, and taking more than one GLP-1 at a time is not permitted.12AmeriHealth Caritas NC. GLP-1 Weight Management Prior Authorization

To keep coverage going, adults must document at least a 5 percent loss of pretreatment weight, and adolescents must show more than a 4 percent reduction in baseline BMI, unless the prescriber documents that a significant reduction is being maintained.13AmeriHealth Caritas NC. Pharmacy Request for Prior Approval: Wegovy Zepbound for obstructive sleep apnea has its own criteria, including a baseline BMI above 40 and a documented sleep apnea diagnosis.14AmeriHealth Caritas NC. Pharmacy Request for Prior Approval: Zepbound

Florida

AmeriHealth Caritas Next in Florida covers Mounjaro, Ozempic, Rybelsus, and Trulicity for type 2 diabetes. As of April 2025, the plan dropped its step-therapy requirement with metformin and now uses a straightforward prior authorization. Qualifying requires a type 2 diabetes diagnosis confirmed by lab results, with an A1C of 6.5 or higher or equivalent glucose thresholds.15AmeriHealth Caritas Next. GLP-1 Medications The plan’s formulary explicitly excludes drugs used for weight loss.16AmeriHealth Caritas Next. Formulary January 2026

Michigan

Michigan Medicaid tightened GLP-1 coverage for weight management on January 1, 2026. Coverage for obesity is now limited to patients with a BMI of 40 or greater who have documented failure of other weight-loss interventions, including preferred anti-obesity medications such as phentermine and Qsymia. The prescriber must also attest that GLP-1 treatment is needed to avoid higher-cost bariatric surgery.17University of Michigan Medicine Research. Expert Q&A: Michigan Medicaid’s New Limits on GLP-1 Weight Management Medications GLP-1s remain covered for type 2 diabetes, Zepbound stays covered for moderate to severe sleep apnea, and Wegovy stays covered for people who are overweight or obese and have established cardiovascular disease or severe liver disease.18Michigan DHHS. Numbered Letter L-25-73 Pharmacy

If AmeriHealth Denies Your GLP-1

A denial is not necessarily the end. On the commercial side, you or your prescriber can request a formulary exception by calling 1-888-678-7012 or faxing 1-888-678-5285. AmeriHealth responds within one business day, and an approved drug is covered at the plan’s highest cost-share tier.19AmeriHealth. Transparency in Coverage

If the exception is denied, the denial letter will explain your appeal rights. You can file an internal appeal by mail, phone (1-888-671-5276), or fax (1-888-671-5274). Standard internal appeals are decided within 72 hours; expedited appeals within 24 hours. In New Jersey, members can request an external review through Maximus, an independent review organization, and AmeriHealth is bound by that decision.19AmeriHealth. Transparency in Coverage

Pennsylvania Medicaid members whose coverage was terminated can file a complaint or grievance through their HealthChoices plan. Filing an appeal within 15 days of the notification letter is intended to keep coverage in place while the appeal is pending.9Pennsylvania Health Law Project. PA Medicaid Ends Adult Coverage of GLP-1s for Weight Loss If no appeal path leads to coverage, Health Savings Account or Flexible Spending Arrangement funds may be an option for paying out of pocket.